Avéli® and Renuvion® Combo Shows Significant Cellulite, Skin Laxity Improvement in New Study
APYX has more than doubled off its 52-week low of $1.36.
Summary
A new clinical study published in Aesthetic Surgery Journal Open Forum demonstrates significant improvement in cellulite and skin laxity using a combination treatment involving Apyx Medical's Renuvion® system. The study reported up to 81.8% of patients showing improvement in cellulite appearance. This positive clinical validation for a core product follows recent expanded FDA clearance for the company's AYON Body Contouring System, which integrates Renuvion, and another study publication earlier this month. The strong data supports the efficacy of Renuvion in a large and growing aesthetic market segment, potentially driving increased adoption and sales.
At the time of this announcement, APYX was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $158.7M. The 52-week trading range was $1.36 to $4.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.